MA34397B1 - Dérivés d'acide napht-2-ylacétique dans le traitement du sida - Google Patents

Dérivés d'acide napht-2-ylacétique dans le traitement du sida

Info

Publication number
MA34397B1
MA34397B1 MA35607A MA35607A MA34397B1 MA 34397 B1 MA34397 B1 MA 34397B1 MA 35607 A MA35607 A MA 35607A MA 35607 A MA35607 A MA 35607A MA 34397 B1 MA34397 B1 MA 34397B1
Authority
MA
Morocco
Prior art keywords
formula
naphth
compounds
acid derivatives
aids
Prior art date
Application number
MA35607A
Other languages
English (en)
Inventor
Kerim Babaoglu
Kyla Bjornson
Hongyan Guo
Randall L Halcomb
John O Link
Ryan Mcfadden
Michael L Mitchell
Paul A Roethle
James D Trenkle
Randall W Vivian
Lianhong Xu
Hongtao Liu
James Taylor
Elizabeth Bacon
Paul Hrvatin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44454746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34397(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA34397B1 publication Critical patent/MA34397B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Image Processing (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

La présente invention concerne des composés de formule (I) : ou l'un de leurs sels comme décrit dans la présente invention. La présente invention concerne également des compositions pharmaceutiques comprenant un composé de formule I, des procédés de synthèse des composés de formule (I), des intermédiaires utiles à la synthèse des composés de formule I et des méthodes thérapeutiques pour le traitement de la prolifération du VIH, le traitement du SIDA ou le retard de l'apparition des symptômes du SIDA ou du complexe associé au SIDA chez un mammifère en utilisant les composés de formule (I).
MA35607A 2010-07-02 2011-07-01 Dérivés d'acide napht-2-ylacétique dans le traitement du sida MA34397B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36131410P 2010-07-02 2010-07-02
PCT/US2011/042880 WO2012003497A1 (fr) 2010-07-02 2011-07-01 Dérivés d'acide napht-2-ylacétique dans le traitement du sida

Publications (1)

Publication Number Publication Date
MA34397B1 true MA34397B1 (fr) 2013-07-03

Family

ID=44454746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35607A MA34397B1 (fr) 2010-07-02 2011-07-01 Dérivés d'acide napht-2-ylacétique dans le traitement du sida

Country Status (28)

Country Link
US (1) US9102614B2 (fr)
EP (1) EP2588450B1 (fr)
JP (2) JP5984218B2 (fr)
KR (1) KR20130135826A (fr)
CN (1) CN103140474A (fr)
AP (1) AP2013006706A0 (fr)
AR (1) AR082079A1 (fr)
AU (1) AU2011274322B2 (fr)
BR (1) BR112013000043A2 (fr)
CA (1) CA2802308C (fr)
CL (1) CL2012003722A1 (fr)
CO (1) CO6660497A2 (fr)
CR (1) CR20130045A (fr)
EA (1) EA201291300A1 (fr)
EC (1) ECSP13012417A (fr)
ES (1) ES2634490T3 (fr)
IL (1) IL223558A0 (fr)
MA (1) MA34397B1 (fr)
MX (1) MX2012015097A (fr)
NZ (1) NZ604598A (fr)
PE (1) PE20130385A1 (fr)
PH (1) PH12013500011A1 (fr)
PT (1) PT2588450T (fr)
SG (1) SG186820A1 (fr)
TW (1) TWI453208B (fr)
UY (1) UY33480A (fr)
WO (1) WO2012003497A1 (fr)
ZA (1) ZA201209596B (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077613A1 (fr) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll (tlr)
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
EP2511273B8 (fr) * 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
EP2793898A1 (fr) 2011-12-22 2014-10-29 Université Laval Cavités tridimensionnelles d'immunorécepteur de cellules dendritiques (dcir), composés se liant à celles-ci et applications thérapeutiques associées à l'inhibition du virus de l'immunodéficience humaine de type 1 (vih-1)
WO2013103738A1 (fr) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide naphtalène acétique contre l'infection par le vih
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2719685A1 (fr) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9012441B2 (en) 2013-01-09 2015-04-21 Gilead Sciences, Inc. Therapeutic compounds
JP5941598B2 (ja) 2013-01-09 2016-06-29 ギリアード サイエンシーズ， インコーポレイテッド ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
TW201441197A (zh) * 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
EP2970298A1 (fr) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2016512507A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
ES2619708T3 (es) 2013-03-13 2017-06-26 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de inmunodeficiencia humana
WO2014159959A1 (fr) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CN105008369B (zh) 2013-03-14 2017-07-11 百时美施贵宝公司 人类免疫缺陷病毒复制抑制剂
EP2821104A1 (fr) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2821082A1 (fr) 2013-07-05 2015-01-07 Laboratoire Biodim Procédé de production d'un lentivirus inactivé, notamment le VIH, vaccin, kit et procédé d'utilisation
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
NO2865735T3 (fr) 2013-07-12 2018-07-21
ES2654242T3 (es) 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
EP3152215A1 (fr) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Macrocycles de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (fr) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Macrocycles d'imidazopyrimidine utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (fr) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2015130964A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Composés thérapeutiques
CN103804211B (zh) * 2014-03-12 2016-04-06 天津市炜杰科技有限公司 4-(乙酰基氨基)-2-羟基-3-(2-羰基乙基)苯甲酸甲酯的合成方法
WO2015174511A1 (fr) * 2014-05-16 2015-11-19 塩野義製薬株式会社 Dérivé hétérocyclique tricyclique présentant un effet d'inhibition de la réplication du vih
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP4140485A1 (fr) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
WO2016036759A1 (fr) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Méthodes de traitement ou de prévention du vih chez des patients au moyen d'une combinaison de ténofovir alafénamide et de dolutégravir
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのイソキノリン化合物
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
WO2016161382A1 (fr) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Composés carbamoylpyridones polycycliques et leur utilisation pharmaceutique
SG11201709634QA (en) * 2015-05-29 2017-12-28 Shionogi & Co Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治療hiv的toll樣受體(tlr)調節劑
ES2797900T3 (es) 2015-09-30 2020-12-04 Gilead Sciences Inc Compuestos y combinaciones para el tratamiento del VIH
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
SI3347352T1 (sl) 2016-08-19 2019-08-30 Gilead Sciences, Inc. Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
WO2018042331A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
WO2018042332A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2018051250A1 (fr) 2016-09-14 2018-03-22 Viiv Healthcare Company Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc
WO2018064080A1 (fr) 2016-09-28 2018-04-05 Gilead Sciences, Inc. Dérivés d'acide benzothiazol-6-yl-acétique et leur utilisation pour le traitement d'une infection par le vih
EP3532478B1 (fr) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Forme crystalline de darunavir base libre
US20200055839A1 (en) 2017-01-03 2020-02-20 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200016136A1 (en) 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2018138050A1 (fr) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
TWI868958B (zh) 2017-01-31 2025-01-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
EP3645003A4 (fr) 2017-06-30 2021-03-10 VIIV Healthcare Company Association, utilisations et schémas thérapeutiques
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP6934562B2 (ja) 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019084020A1 (fr) 2017-10-24 2019-05-02 Gilead Sciences, Inc. Méthodes de traitement de patients co-infectés par un virus et la tuberculose
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3728283B1 (fr) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
AU2019209594B2 (en) 2018-01-19 2021-09-23 Gilead Sciences, Inc. Metabolites of bictegravir
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CR20200653A (es) 2018-07-03 2021-02-11 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y métodos de uso
JP7049519B2 (ja) 2018-07-06 2022-04-06 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CA3103522C (fr) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Inhibiteurs de capsides pour le traitement du vih
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
JP7313438B2 (ja) 2018-09-19 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの予防のためのインテグラーゼ阻害剤
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
WO2020176505A1 (fr) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Agonistes de protéine kinase c
WO2020176510A1 (fr) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Agonistes de protéine kinase c
EP3935065A1 (fr) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting
EP3934757B1 (fr) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides cycliques en 2'3' et leurs promédicaments
CA3129011C (fr) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Dinucleotides 3'3'-cycliques et leurs promedicaments
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CA3140708A1 (fr) 2019-06-18 2020-12-24 Helen Horton Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
CA3145791A1 (fr) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Vaccins contre le vih et leurs procedes de fabrication et d'utilisation
WO2021011891A1 (fr) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Formulations à action prolongée de ténofovir alafénamide
WO2021034804A1 (fr) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Formulations pharmaceutiques de ténofovir alafénamide
TW202519228A (zh) 2019-11-26 2025-05-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
WO2021104470A1 (fr) * 2019-11-29 2021-06-03 南京明德新药研发有限公司 Composé de 1,7-naphtyridine anti-vhb
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021236944A1 (fr) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Compositions pharmaceutiques contenant du bictégravir
EP4172157B1 (fr) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de capside pour le traitement du vih
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4660325A3 (fr) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Procédés d'identification de patients vih sensibles à une thérapie avec des anticorps dirigés contre le site de liaison de la gp120 cd4
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102529A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composés thérapeutiques pour l'infection par le virus du vih
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds
WO2024249592A1 (fr) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Dérivés de quinazolinyl-indazole en tant que composés thérapeutiques pour le vih
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
CN117326921B (zh) * 2023-09-27 2026-03-06 山东京博农化科技股份有限公司 一种1-(2,4,6-三氯苯基)-丙基-2-酮的制备方法
WO2025076542A1 (fr) 2023-10-05 2025-04-10 Jones R Brad Atovaquone comme inducteur de ros destiné à être utilisé dans l'élimination de lymphocytes t infectés par le vih
WO2025080879A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
WO2025080850A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'intégrase du vih
WO2025184609A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Composés antiviraux
US20250326779A1 (en) 2024-04-03 2025-10-23 Gilead Sciences, Inc. Anti-hiv compounds
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895028A (en) 1972-09-12 1975-07-15 Tokyo Tanabe Co Alpha-(2-phenylbenzothiazol-5-yl)propionic acid
JPS4994667A (fr) 1973-01-23 1974-09-09
FR2453163A1 (fr) 1979-04-03 1980-10-31 Rolland Sa A Derives de benzothiazole, leur procede de preparation et leurs applications en therapeutique
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
GB8403739D0 (en) 1984-02-13 1984-03-14 Roussel Lab Ltd Chemical compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JPH03287558A (ja) 1990-04-05 1991-12-18 Teijin Ltd 酵素阻害剤
EP0533833B1 (fr) 1990-06-13 1995-12-20 GLAZIER, Arnold Promedicaments phosphoreux
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5733906A (en) 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
CA2159639A1 (fr) 1993-04-02 1994-10-13 Vincent J. Miles Methode pour l'inactivation selective de la replication virale
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
DE4428932A1 (de) 1994-08-16 1996-02-22 Hoechst Ag Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
EP1070040A1 (fr) 1998-04-09 2001-01-24 Merck & Co., Inc. Procede d'oxydation au moyen d'acide periodique
WO2000063152A1 (fr) 1999-02-22 2000-10-26 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Analogues acetyles et correspondants d'acide chicorique en tant qu'inhibiteurs de l'integrase du vih
US20020052323A1 (en) 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
MXPA03004435A (es) 2000-11-21 2005-01-25 Sunesis Pharmaceuticals Inc Procedimiento de traba extendida para identificacion rapida de ligandos.
FR2819507B1 (fr) 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
JP2004043416A (ja) * 2001-08-16 2004-02-12 Japan Tobacco Inc β−ケトアミド化合物及びその医薬用途
FR2839646B1 (fr) 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
US20050267156A1 (en) 2002-08-02 2005-12-01 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
CA2496565C (fr) * 2002-08-23 2013-04-02 Ribapharm Inc. Inhibiteurs non nucleosidiques de transcriptases inverses
EP1546331B2 (fr) 2002-09-26 2016-01-13 K.U.Leuven Research & Development Cofacteur de l'integrase
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7776883B2 (en) * 2004-03-10 2010-08-17 The United States Of America As Represented By The Department Of Health And Human Services Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC)
WO2006001958A2 (fr) 2004-05-21 2006-01-05 Merck & Co., Inc. Modulateurs heterocycliques et carbocycliques d'amino cyclopentyle de l'activite du recepteur de la chimiokine
US7087610B2 (en) 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
CN101006042A (zh) 2004-06-22 2007-07-25 史密丝克莱恩比彻姆公司 化合物
TWI306401B (en) 2004-08-13 2009-02-21 Nat Health Research Institutes Benzothiazolium compounds
US20060094755A1 (en) 2004-10-28 2006-05-04 Bioflexis, Llc Novel quinoline-based metal chelators as antiviral agents
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2006124780A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
JP2009515882A (ja) 2005-11-10 2009-04-16 シェーリング コーポレイション プロテインキナーゼを阻害するための方法
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2651979A1 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Derives de la triazolopyridazine
JO2841B1 (en) 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
US8435774B2 (en) 2006-06-28 2013-05-07 Qiagen Gmbh Enhancing reactivation of thermostable reversibly inactivated enzymes
WO2008053478A2 (fr) 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions et procédés pour inhiber la réplication et l'activité de l'intégrase du vih-1
AU2007332654B2 (en) * 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
US7956068B2 (en) 2007-11-15 2011-06-07 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
GB0801940D0 (en) 2008-02-01 2008-03-12 Univ Leuven Kath Inhibitors of lentiviral replication
EP2265270A1 (fr) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
EP2196453A1 (fr) * 2008-12-10 2010-06-16 Cellvir Nouveaux dérivés aryle substitués, leur procédé de préparation et leurs utilisations thérapeutiques en tant qu'agents anti-VIH
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
MX336687B (es) 2009-06-30 2016-01-28 Siga Technologies Inc Tratamiento y prevencion de infecciones del virus del dengue.
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
NZ610315A (en) 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
CA2817896A1 (fr) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibiteurs de la replication du vih
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
AU2012209373A1 (en) 2011-01-24 2013-04-11 Glaxosmithkline Llc Isoquinoline compounds and methods for treating HIV
JP2014511859A (ja) 2011-04-04 2014-05-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス
CA2830845A1 (fr) 2011-04-04 2012-10-11 Gilead Sciences, Inc. Formes a l'etat solide d'un inhibiteur du vih
EP2508511A1 (fr) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2511273B8 (fr) * 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013002357A1 (fr) 2011-06-30 2013-01-03 塩野義製薬株式会社 Inhibiteur de réplication du vih
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
WO2013058448A1 (fr) 2011-10-20 2013-04-25 한국해양연구원 Gènes de medaka marin répondant à l'exposition à des substances chimiques perturbant le système endocrinien et procédé destiné à diagnostiquer une pollution d'un écosystème aquatique les utilisant
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013103738A1 (fr) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide naphtalène acétique contre l'infection par le vih
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013157622A1 (fr) 2012-04-19 2013-10-24 塩野義製薬株式会社 Inhibiteur de la réplication du vih
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
PT2877468T (pt) 2012-07-12 2017-11-21 Viiv Healthcare Uk Ltd Compostos e métodos para o tratamento de vih
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
WO2014055603A1 (fr) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Procédé de préparation d'un inhibiteur d'intégrase du vih

Also Published As

Publication number Publication date
UY33480A (es) 2012-02-29
AP2013006706A0 (en) 2013-02-28
CA2802308C (fr) 2018-08-28
ZA201209596B (en) 2015-06-24
EA201291300A1 (ru) 2013-06-28
IL223558A0 (en) 2013-03-05
AU2011274322B2 (en) 2015-08-13
US9102614B2 (en) 2015-08-11
KR20130135826A (ko) 2013-12-11
CR20130045A (es) 2013-05-16
AR082079A1 (es) 2012-11-07
MX2012015097A (es) 2013-05-28
US20130203727A1 (en) 2013-08-08
SG186820A1 (en) 2013-02-28
PT2588450T (pt) 2017-08-03
EP2588450B1 (fr) 2017-05-24
CL2012003722A1 (es) 2014-03-21
PE20130385A1 (es) 2013-03-30
BR112013000043A2 (pt) 2019-09-24
TWI453208B (zh) 2014-09-21
PH12013500011A1 (en) 2013-02-18
AU2011274322A1 (en) 2013-01-10
NZ604598A (en) 2014-12-24
CN103140474A (zh) 2013-06-05
JP2013535426A (ja) 2013-09-12
CO6660497A2 (es) 2013-04-30
TW201215614A (en) 2012-04-16
CA2802308A1 (fr) 2012-01-05
EP2588450A1 (fr) 2013-05-08
WO2012003497A1 (fr) 2012-01-05
JP5984218B2 (ja) 2016-09-06
JP2015193671A (ja) 2015-11-05
ECSP13012417A (es) 2013-03-28
ES2634490T3 (es) 2017-09-28

Similar Documents

Publication Publication Date Title
MA34397B1 (fr) Dérivés d&#39;acide napht-2-ylacétique dans le traitement du sida
MA34400B1 (fr) Dérivés d&#39;acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih
MA35804B1 (fr) Modulation de l&#39;expression du virus de l&#39;hepatite b (vhb)
MA32598B1 (fr) Nouveaux benzamides, leur preparation et leur utilisation comme medicaments
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
TN2009000450A1 (fr) Derives de pyridine
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MA32351B1 (fr) Derives d&#39;aminodihydrothiazine a titre d&#39;inhibiteurs de bace pour le traitement de la maladie d&#39;alzheimer
MA29926B1 (fr) Derives de pyrazine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu&#39;agents antibactériens et inhibiteurs de ß-lactamase
MA33745B1 (fr) Piperidines substituees qui accroissent l&#39;activite de p53, et utilisation de ces composes
MA32965B1 (fr) Derives de sulfonamides
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA34896B1 (fr) Inhibiteurs du virus de l&#39;hepatite c
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA31919B1 (fr) Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
MA35104B1 (fr) Inhibiteur du virus de l&#39;hepatite c
MA32108B1 (fr) Derives d&#39;indazole
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales